Study of SPH5030 for HER2-positive advanced colorectal or bile duct cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal or biliary tract cancer that has spread or cannot be removed with surgery.
- Your tumor is HER2-positive (high HER2 protein) or has a HER2 gene mutation.
- You have already received standard treatments for your cancer before.
- You are in good physical condition (able to do daily activities, ECOG 0 or 1).
- You have not had anti-HER2 therapy before (like trastuzumab).
- You are not pregnant or breastfeeding and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (KN026 plus chemotherapy, with or without KN-046) for people with HER2-positive colorectal or bile duct cancer that has spread. The goal is to see if this treatment can help shrink or control the cancer.
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Hear when a new Biliary Tract or Colorectal Cancer With Her2-positive/Mutated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.